Last Update: 2024-03-28 02:12:56
Seres Therapeutics Inc. ( MCRB ) https://www.serestherapeutics.com
United States
Historical Returns*:
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Other Earnings and Cash Flow Stats:
Seres Therapeutics Inc. ( MCRB ) Net Income TTM ($MM) is -249.82
Seres Therapeutics Inc. ( MCRB ) Operating Income TTM ($MM) is -245.39
Seres Therapeutics Inc. ( MCRB ) Owners' Earnings Annual ($MM) is -108.86
Seres Therapeutics Inc. ( MCRB ) Current Price to Owners' Earnings ratio is -0.93
Seres Therapeutics Inc. ( MCRB ) EBITDA TTM ($MM) is -239.16
Seres Therapeutics Inc. ( MCRB ) EBITDA Margin is -86.57%
Capital Allocation:
Seres Therapeutics Inc. ( MCRB ) has paid 0.00 dividends per share and bought back -26.964424 million shares in the past 12 months
Seres Therapeutics Inc. ( MCRB ) has reduced its debt by 65.103 million USD in the last 12 months
Capital Structure:
Seres Therapeutics Inc. ( MCRB ) Interest-bearing Debt ($MM) as of last quarter is 101
Seres Therapeutics Inc. ( MCRB ) Annual Working Capital Investments ($MM) are 5
Seres Therapeutics Inc. ( MCRB ) Book Value ($MM) as of last quarter is -45
Seres Therapeutics Inc. ( MCRB ) Debt/Capital as of last quarter is -227%
Other Balance Sheet Stats:
Seres Therapeutics Inc. ( MCRB ) has 127 million in cash on hand as of last quarter
Seres Therapeutics Inc. ( MCRB ) has 98 million of liabilities due within 12 months, and long term debt 101 as of last quarter
Seres Therapeutics Inc. ( MCRB ) has 135 common shares outstanding as of last quarter
Seres Therapeutics Inc. ( MCRB ) has 0 million USD of preferred stock value
Academic Scores:
Seres Therapeutics Inc. ( MCRB ) Altman Z-Score is -4.12 as of last quarter
Seres Therapeutics Inc. ( MCRB ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Seres Therapeutics Inc. ( MCRB ) largest shareholder is owning shares at 0.00 ($MM) value
Teresa L Young(an insider) Sold 3374 shares of Seres Therapeutics Inc. ( MCRB ) for the amount of $3643.92 on 2024-02-16
6.75% of Seres Therapeutics Inc. ( MCRB ) is held by insiders, and 80.44% is held by institutions
Seres Therapeutics Inc. ( MCRB ) went public on 2015-06-26
Other Seres Therapeutics Inc. ( MCRB ) financial metrics:
Unlevered Free Cash Flow:-92.22
Operating Margin:-15294.52
Gross Profit Margin:-67.42
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:426.73
Buffet's Owners Earnings:-108.86
Price to Owner's Earnings:-0.93
About Seres Therapeutics Inc. ( MCRB ) :
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
User Content from Tickernomics. Created by Luminus.

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.